FDA revises guidance on IRB review of expanded access submissions to reflect end of public health emergency
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaPharmaceuticalsRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaPharmaceuticals